Allo HSCT for High Risk Hemoglobinopathies
Phase 2
62
about 7.5 years
≤55
1 site in MN
What this study is about
Researchers are testing a treatment called allogeneic hematopoietic stem cell transplantation (HSCT) for people with high-risk hemoglobinopathies and other conditions that require frequent blood transfusions. The trial will involve using various medications, including chemotherapy drugs, to prepare the patient before the transplant.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Cell Infusion
- 2.Receive Total Body Irradiation
- 3.Take Alemtuzumab
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
alemtuzumab, busulfan, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, Immunological Agents (Enzyme Inhibitors), sirolimus, tacrolimus, thiotepa
injection (Injection), injection, intravenous, infusion
Secondary: Overall Survival
radiation